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Anticyclic Citrullinated Peptide Antibodies as Markers of
Erosive Arthritis in Antisynthetase Syndrome
To the Editor:
We read with interest the recent letter by Nagashima, et al1, who suggest-
ed that destructive/erosive arthropathy in anti-Jo-1-positive patients with
dermatomyositis (DM) sine myositis is another disease subset, classifiable
as DM sine myositis overlapping with rheumatoid arthritis (RA).
Moreover, the authors state that anticyclic citrullinated peptide antibodies
(anti-CCP) are useful for distinguishing subluxing from destructive
arthropathy in this setting. We describe our experience on the topic.
We have followed 12 anti-Jo-1-positive patients (8 women, 4 men, ages
46–78 yrs) with antisynthetase syndrome (Table 1). The disease spectrum
is characterized by the occurrence of cutaneous findings in all cases
(“mechanic’s hands”), interstitial lung involvement in all cases (by chest
high resolution computed tomography, pulmonary function tests, and
DLCO), myositis (8/12 patients; muscle biopsy), and arthritis (11/12
patients; clinical observation). All arthritis patients satisfied American
College of Rheumatology classification criteria for RA (symmetrical
arthritis of wrists and metacarpophalangeal and proximal interphalangeal
joints, prolonged morning stiffness); the single patient without arthritis had
inflammatory hand pain. Low titer IgM rheumatoid factor (RF; by
immunonephelometry) was found in 3 patients (with 29, 42, and 78 IU/ml,
normal value < 20), whereas anti-CCP antibodies (commercial second-gen-
eration ELISA kit) were present in 2 patients (with 14 and 162 IU/ml, nor-
mal value < 6), together with RF. Erosions were assessed by radiographs of
hands and feet. Marginal erosions were found in 2 patients who were
anti-CCP-positive. Joint erosions were statistically associated with
anti-CCP (p = 0.045, Fisher’s exact test) but not with RF-IgM (p = 0.127).
With regard to the cases described by Nagashima, et al, all our patients
with erosive arthritis also had clinical and biopsy-proven inflammatory
myositis; we also confirmed the association between erosivity and
anti-CCP in anti-Jo-1-positive patients. To date there are several reports
evaluating the meaning of anti-CCP antibodies in connective tissue dis-
eases other than RA; in systemic sclerosis (SSc)2 and systemic lupus ery-
thematosus (SLE)3 these antibodies are markers of erosive arthritis, as we
suggest in antisynthetase syndrome. In contrast, in Sjögren’s syndrome4
this association is lacking, although anti-CCP seem to be closely associat-
ed with the occurrence of synovitis.
Taking the literature data into account, we suggest that a RA-like arthri-
tis may be present in patients who are anti-Jo-1-positive, independent of
the occurrence of myositis. Moreover, the risk of erosive disease in this set-
ting is closely related to anti-CCP positivity, similarly to SSc and SLE.
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Table 1. Characteristics of anti-Jo-1-positive patients with antisynthetase syndrome.
Patient Sex/Age Followup, yrs ILD Myositis RA-like Joint Anti-ENA Anti-CCP, RF, IU/ml
Arthritis Erosions IU/ml
1 M 78 4 Yes Yes Yes No Jo-1/Ro Neg Neg
2 M 57 5 Yes No No No Jo-1 Neg Neg
3 F 74 3 Yes Yes Yes No Jo-1 Neg Neg
4 F 78 6 Yes No Yes No Jo-1/Ro Neg 42
5 M 73 4 Yes No Yes No Jo-1/Ro Neg Neg
6 F 78 7 Yes Yes Yes No Jo-1 Neg Neg
7 M 46 3 Yes Yes Yes Yes Jo-1/Ro 14 29
8 F 56 9 Yes Yes Yes No Jo-1/Ro Neg Neg
9 F 78 5 Yes Yes Yes No Jo-1 Neg Neg
10 F 63 11 Yes Yes Yes No Jo-1/Ro Neg Neg
11 F 57 10 Yes No Yes No Jo-1 Neg Neg
12 F 62 3 Yes Yes Yes Yes Jo-1 162 78
ILD: interstitial lung disease; RA: rheumatoid arthritis; ENA: extractable nuclear antigen antibodies; CCP: citric citrullinated peptide antibodies; RF: rheuma-
toid factor.
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